fb-pixel Skip to main content

Latest Headlines in Biotech


An image of "endless RNA," or eRNA, shows how the engineered molecule can latch onto a ribosome to make proteins.

Laronde, a Flagship Pioneering startup, aims to make protein-based drugs in the body with ‘endless RNA’

Backed by $50 million in funding, a small team from Flagship Pioneering has been working to engineer a type of RNA molecule that can continuously make therapeutic proteins inside the body.

Founder and chief scientific officer of Talaris, Suzanne Ildstad, and chief executive Scott Requadt.

Talaris completes $150 million IPO as it goes after organ-transplant drugs

Talaris Therapeutics, a biotech founded nearly 20 years ago, has gone public in the latest initial public offering in the local life sciences industry.

Moderna CEO Stephane Bancel.

Moderna’s CEO says he ‘didn’t lose a minute of sleep’ over potential waiver of vaccine patents

Chief executive Stephane Bancel said there aren’t enough manufacturing sites or skilled workers in the world to rapidly ramp up the supply of messenger RNA vaccines.

Dyno Therapeutics chief executive Eric Kelsic.

Dyno raises $100 million to bring artificial intelligence to gene therapy

Cambridge-based Dyno remained in stealth mode until March 2020, then quickly made a splashy debut, inking deals with Novartis, Sarepta, and Roche.

Moderna’s production and lab facility in Norwood.

Moderna reports first profit, says early data show vaccine is 96 percent effective in adolescents

While Moderna recorded its first-ever profitable quarter, revenues of $1.94 billion came in below Wall Street expectations.

Biogen's headquarters in Cambridge.

Drug pricing watchdog says there’s ‘insufficient’ evidence that Biogen’s Alzheimer’s medicine would help patients

In a draft report, Boston-based ICER cites conflicting data from two trials. The Cambridge biotech says it “does not accurately reflect the possible holistic value” of the experimental treatment.

Moderna’s production and lab building in Norwood.

Moderna booster shots show encouraging results against variants

The Cambridge biotech releases early study data showing the vaccine’s effect on antibody levels.

President Biden speaking about COVID-19 vaccinations last month.

Biden administration backs waiver of intellectual property protections for COVID-19 vaccines

The Biden administration is throwing its support behind efforts to waive intellectual property protections for COVID-19 vaccines in an attempt to speed the end of the pandemic.